# Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes

> **NCT03334214** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 44 (actual)

## Conditions studied

- Hepatic Steatosis

## Interventions

- **DRUG:** IONIS DGAT2Rx
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03334214
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-03
- **Primary completion:** 2018-11-28
- **Final completion:** 2018-11-28
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03334214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03334214, "Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03334214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*